findmyKOL

Michael Ragosta, MD

Basic profile

University of Virginia Health System

ORCIDNPI
RegionCharlottesville, VA · SoutheastSpecialtyInterventional CardiologyFocusCardiology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Michael Ragosta is a Cardiology physician affiliated with University of Virginia Health System. OpenAlex indexes 294 publications with 8,901 citations (h-index 42). By OpenAlex citation count, this profile ranks in the top 10% of Interventional Cardiology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
294publications

Distinct works indexed by OpenAlex, matched via ORCID.

8,901citations

Total citations across indexed works.

42h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    76.2%
    Beta blocker18.6%
    Metoprolol Succinate48%Carvedilol24%Metoprolol Tartrate21%Atenolol7%
    Part D<11 patients
    Statin16.9%
    Atorvastatin Calcium71%Rosuvastatin Calcium29%
    Part D42 patients

    + 10 more classes in this area

  • Blood & clotting

    22.4%
    P2Y12 inhibitor15.9%
    Clopidogrel92%Prasugrel Hcl8%
    Part D<11 patients
    Factor Xa inhibitor6.5%
    Eliquis86%Xarelto14%
    Part D<11 patients
  • Metabolism & gastrointestinal

    1.4%
    Proton pump inhibitor1.4%
    Pantoprazole Sodium100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”